Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Göttingen, Göttingen, Germany.
Department of Otorhinolaryngology, Ludwig-Maximilians University of Munich, Munich, Germany.
Head Neck. 2019 Sep;41(9):3144-3158. doi: 10.1002/hed.25806. Epub 2019 Jun 10.
Oncological and functional outcome of transoral laser microsurgery (TLM) for primary treatment of oropharyngeal cancer was examined using a multimodal treatment concept.
A total of 368 patients with oropharyngeal squamous cell carcinoma (pT1-4, pN0-2, M0) underwent TLM +/- neck dissection (85%), +/- (chemo)radiotherapy (57%). The majority of patients had advanced stage III and IVa disease (79%).
Five-year Kaplan-Meier estimates for local control were 83.5% for pT1, 74.1% for pT2, 77.3% for pT3, and 76.0% for pT4a tumors. Five-year estimates of overall, disease-specific, and recurrence-free survival for stage I were 76.0%, 92.8%, and 69.1%; for stage II 71.1%, 85.7%, and 49.6%; for stage III 61.7%, 72.5%, and 58.8%; and for stage IVa 57.3%, 73.7%, and 63.9%, respectively. Postoperative (chemo)radiotherapy improved the outcome for advanced disease. p16-positive tumors had superior survival estimates. Overall, 93.5% maintained regular oral nutrition without feeding tube dependency.
Primary TLM in multimodal concepts of treatment offers good oncologic outcome even for advanced-stage oropharyngeal cancer.
通过多模式治疗方案,我们研究了经口激光微创手术(TLM)作为原发治疗用于口咽鳞癌的肿瘤学和功能学结果。
368 例口咽鳞癌(pT1-4、pN0-2、M0)患者接受 TLM +/-颈清扫术(85%), +/-(放)化疗(57%)。大多数患者为 III 期和 IVa 期(79%)晚期疾病。
TLM 治疗的局部控制的 5 年 Kaplan-Meier 估计值为:pT1 为 83.5%,pT2 为 74.1%,pT3 为 77.3%,pT4a 为 76.0%。I 期、II 期、III 期和 IVa 期的总生存率、疾病特异性生存率和无复发生存率的 5 年估计值分别为 76.0%、92.8%和 69.1%;71.1%、85.7%和 49.6%;61.7%、72.5%和 58.8%;57.3%、73.7%和 63.9%。术后(放)化疗可改善晚期疾病的预后。p16 阳性肿瘤具有更好的生存估计值。总体而言,93.5%的患者能够维持常规的口腔营养,无需依赖喂养管。
多模式治疗方案中的原发 TLM 甚至为晚期口咽鳞癌提供了良好的肿瘤学结果。